12 results
Autoantibodies in Rheumatology
 • Lupus (SLE): ANA (anti-nuclear antibody), dsDNA (double-stranded DNA), Anti-Smith, Anti-Ro (SSA) and
Autoantibodies in Rheumatology ... • Lupus (SLE): ... Autoantibodies #Rheumatology ... #diagnosis #associations ... #table
Connective tissue disease-associated interstitial lung diseases

LIP: lymphoid interstitial pneumonia. NSIP: nonspecific interstitial pneumonia. OP: organizing pneumonia.
SLE : systemic lupus ... Differential #Comparison #Table ... #Pulmonary #Rheumatology ... #Associations
Antinuclear antibodies and Systemic lupus
Anti-dsDNA	60-80%	Association with disease activity (when with Farr assay) and lupus nephritis. Can
Anti-dsDNA 60-80% Association ... Controversial association ... Negative association ... erythematosus #diagnosis #rheumatology ... #table #ANA
Thrombotic Microangiopathy - TTP VS HUS

Big picture points : Often hard to differentiate the two entities,
distinction has HUGE treatment ... and first-line treatment ... Comparison #Diagnosis #Table ... #Hematology
Managing warfarin INR

Warfarin dosage must be individualized according to the patient's response to the drug, and
#pharmacology #treatment ... #medications #table ... decisionaid #cardiology #hematology
Drug Induced Lupus vs SLE
Drug Induced Lupus (DIL):
 • Epidemiology: -10% of all lupus cases, drug-dependent,
Drug Induced Lupus ... constitutional symptoms • Treatment ... life-threatening • Treatment ... sle #comparison #table ... #rheumatology #
Diagnostic Criteria for Sweet Syndrome (Acute Febrile Neutrophilic Dermatosis)
Major criteria 
 1. Abrupt onset of tender
Association with ... an underlying hematologic ... Excellent response to treatment ... Criteria #Diagnosis #Hematology ... #Dermatology
Idiopathic Inflammatory Myopathies (IIM's)

RASH + MUSCLE WEAKNESS → Consider idiopathic inflammatory myopathies (IIM's)

 • Overlap Myositis
that occurs in association ... skeletal muscles • NAM ... IIMs #diagnosis #rheumatology ... #dermatology #Myopathy
TRALI vs TACO - Transfusion Reactions
TRALI:
 • Epidemiology: 0.1% of transfused patientsl
 • Risk factors: Critical
: 33% • Treatment ... : No • Treatment ... Transfusion #Reactions #hematology ... diagnosis #comparison #table
(DOAC interactions) Cancer-treatment specific inducers (↑) and inhibitors (↓)
of cytochrome p450 CYP3A4 and P-glycoprotein.

DOACs are substrates
interactions) Cancer-treatment ... Chemotherapy #Oncology #Hematology ... #Interactions #Table